Serum cytokine profiles in patients with pancreatic cancer and chronic pancreatitis.

[1]  J. Laukkarinen,et al.  Plasma soluble urokinase-type plasminogen activator receptor (P-suPAR) in the diagnostics between malignant and non-malignant pancreatic lesions. , 2022, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[2]  C. Pilarsky,et al.  Independent validation and assay standardization of improved metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. , 2022, Gastroenterology.

[3]  A. Carrato,et al.  Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis , 2021, EBioMedicine.

[4]  F. Ferreira,et al.  Tumor microenvironment of human breast cancer, and feline mammary carcinoma as a potential study model. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[5]  S. Jalkanen,et al.  A prognostic model for colorectal cancer based on CEA and a 48-multiplex serum biomarker panel , 2021, Scientific Reports.

[6]  D. Leucuta,et al.  Inflammation, Tumoral Markers and Interleukin-17, -10, and -6 Profiles in Pancreatic Adenocarcinoma and Chronic Pancreatitis , 2020, Digestive Diseases and Sciences.

[7]  M. Cybulski,et al.  Serum miR-210-3p can be used to differentiate between patients with pancreatic ductal adenocarcinoma and chronic pancreatitis , 2020, Biomedical reports.

[8]  C. Haglund,et al.  Association between chronic pancreatitis and pancreatic cancer: A 10‐year retrospective study of endoscopically treated and surgical patients , 2020, International journal of cancer.

[9]  Walter G. Park,et al.  Unique circulating immune signatures for recurrent acute pancreatitis, chronic pancreatitis and pancreatic cancer: A pilot study of these conditions with and without diabetes. , 2019, Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.].

[10]  P. Wagle,et al.  Diagnosis and Management of Pancreatic Adenocarcinoma in the Background of Chronic Pancreatitis: Core Issues , 2019, Digestive Diseases.

[11]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[12]  A. Skulimowski,et al.  Growth differentiation factor (GDF-15) concentration combined with Ca125 levels in serum is superior to commonly used cancer biomarkers in differentiation of pancreatic mass. , 2017, Cancer biomarkers : section A of Disease markers.

[13]  V. Salomaa,et al.  Plasma levels of hepatocyte growth factor and placental growth factor predict mortality in a general population: a prospective cohort study , 2017, Journal of internal medicine.

[14]  R. Pfeiffer,et al.  Impact of freeze‐thaw cycles on circulating inflammation marker measurements , 2017, Cytokine.

[15]  O. Raitakari,et al.  Circulating Cytokines Predict the Development of Insulin Resistance in a Prospective Finnish Population Cohort. , 2016, The Journal of clinical endocrinology and metabolism.

[16]  W. Greenhalf,et al.  Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease , 2014, Molecular Cancer.

[17]  E. Kuipers,et al.  Prevalence of Autoimmune Pancreatitis and Other Benign Disorders in Pancreatoduodenectomy for Presumed Malignancy of the Pancreatic Head , 2012, Digestive Diseases and Sciences.

[18]  M. Karin,et al.  Immunity, Inflammation, and Cancer , 2010, Cell.

[19]  G. Klöppel,et al.  Chronic pancreatitis and the differential diagnosis versus pancreatic cancer. , 2009, Archives of pathology & laboratory medicine.

[20]  I. Tannock,et al.  Cytokines and their relationship to the symptoms and outcome of cancer , 2008, Nature Reviews Cancer.

[21]  A. Masamune,et al.  Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. , 2008, American journal of physiology. Gastrointestinal and liver physiology.

[22]  D. McMillan,et al.  Chronic inflammation and pancreatic cancer. , 2008, Best practice & research. Clinical gastroenterology.

[23]  A. Bjartell,et al.  The proinflammatory CXC-chemokines GRO-α/CXCL1 and MIG/CXCL9 are concomitantly expressed in ulcerative colitis and decrease during treatment with topical corticosteroids , 2007, International Journal of Colorectal Disease.

[24]  D. Finkelstein,et al.  Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R. Bell,et al.  Incidence of benign inflammatory disease in patients undergoing Whipple procedure for clinically suspected carcinoma: a single-institution experience. , 2006, American journal of surgery.

[26]  Y. Tian,et al.  The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. , 2005, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[27]  L. Coussens,et al.  Inflammation and cancer , 2002, Nature.

[28]  H. Soto,et al.  CCL27–CCR10 interactions regulate T cell–mediated skin inflammation , 2002, Nature Medicine.

[29]  S. Weitzman,et al.  Chronic inflammation and cancer. , 2002, Oncology.

[30]  T. Murakami,et al.  Pancreatic mass due to chronic pancreatitis: correlation of CT and MR imaging features with pathologic findings. , 2001, AJR. American journal of roentgenology.

[31]  J. Fraumeni,et al.  The risk of pancreatic cancer following pancreatitis: an association due to confounding? , 1997, Gastroenterology.

[32]  Stephen H. Lee,et al.  Chronic pancreatitis , 1991, The Lancet.

[33]  A. Gee,et al.  Nerve growth factor: stimulation of polymorphonuclear leukocyte chemotaxis in vitro. , 1983, Proceedings of the National Academy of Sciences of the United States of America.

[34]  B. Mroczko,et al.  Diagnostic usefulness of serum interleukin 6 (IL‐6) and C‐reactive protein (CRP) in the differentiation between pancreatic cancer and chronic pancreatitis , 2010, Journal of clinical laboratory analysis.

[35]  D. Landsittel,et al.  Multianalyte profiling of serum cytokines for detection of pancreatic cancer. , 2005, Cancer biomarkers : section A of Disease markers.

[36]  B. Mroczko,et al.  Hematopoietic cytokines in the sera of patients with pancreatic cancer , 2005, Clinical chemistry and laboratory medicine.

[37]  R. Tibshirani.  Regression Shrinkage and Selection via the Lasso , 1996 .